Biodexa Pharmaceuticals ( NASDAQ: BDRX ) said it received $7 million of gross proceeds through the exercise of previously issued warrants and an agreement between the company and several accredited investors. The agreement was for the exercise of certain existing Series E warrants and Series F warrants to buy up to an aggregate of 4.36M of the firm's American depositary shares.
More on Biodexa Pharmaceuticals Biodexa rallies 80% on positive Phase 2 data for eRapa Biodexa shares rally 126% on rapamycin licensing deal.
